Min S Park
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Min S Park has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Alexander Joseph Lazar
Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas
1 shared publication - Daniela Katz
Sharett Institute of Oncology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
1 shared publication - Dejka M. Araujo
Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd. Unit 450, Houston, TX 77030, USA
1 shared publication - Haesun Choi
Department of Abdominal Imaging, Unit 1473, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA
1 shared publication - Lianchun Xiao
Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
1 shared publication - Piyaporn Boonsirikamchai
Department of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
1 shared publication
Latest Publications
- Open Access
- 24 January 2012
- Published by Springer Nature in Clinical Sarcoma Research
- Vol. 2 (1) , 2
Efficacy of first-line doxorubicin and ifosfamide in myxoid liposarcoma
Background: Myxoid liposarcoma (MLS) is a soft tissue sarcoma with adipocytic differentiation characterized by a unique chromosome rearrangement, t(12;16)(q13;p11). The exact efficacy of chemotherapy in MLS has not been clearly established. Patients and methods: We retrospectively analyzed the records of 37 histologically confirmed MLS patients who were treated at the University of Texas MD Anderson Cancer Center from January 2000 to December 2009 with doxorubicin 75-90 mg/m2 over 72 hours combined with ifosfamide 10 gm/m2 in the first-line setting. Response was assessed using RECIST and Choi criteria. The Kaplan-Meier method and log-rank test was used to estimate clinical outcomes. Results: The median follow-up period was 50.1 months. The overall response rates were 43.2% using RECIST and 86.5% using the Choi criteria. The 5-year disease-free survival rate was 90% for patients with resectable tumors. Median time to progression and overall survival time for the advanced-disease group were 23 and 31.1 months, respectively. Conclusion: Our study demonstrates that doxorubicin-ifosfamide combination therapy has a role in the treatment of MLS. The Choi criteria may be more sensitive in evaluating response to chemotherapy in MLS.
- 24 January 2012
- Published by Springer Nature in Clinical Sarcoma Research
- Vol. 2 (1) , 2
Open AccessEfficacy of first-line doxorubicin and ifosfamide in myxoid liposarcoma
Background: Myxoid liposarcoma (MLS) is a soft tissue sarcoma with adipocytic differentiation characterized by a unique chromosome rearrangement, t(12;16)(q13;p11). The exact efficacy of chemotherapy in MLS has not been clearly established. Patients and methods: We retrospectively analyzed the records of 37 histologically confirmed MLS patients who were treated at the University of Texas MD Anderson Cancer Center from January 2000 to December 2009 with doxorubicin 75-90 mg/m2 over 72 hours combined with ifosfamide 10 gm/m2 in the first-line setting. Response was assessed using RECIST and Choi criteria. The Kaplan-Meier method and log-rank test was used to estimate clinical outcomes. Results: The median follow-up period was 50.1 months. The overall response rates were 43.2% using RECIST and 86.5% using the Choi criteria. The 5-year disease-free survival rate was 90% for patients with resectable tumors. Median time to progression and overall survival time for the advanced-disease group were 23 and 31.1 months, respectively. Conclusion: Our study demonstrates that doxorubicin-ifosfamide combination therapy has a role in the treatment of MLS. The Choi criteria may be more sensitive in evaluating response to chemotherapy in MLS.